Connor, Clark & Lunn Investment Management (CC&L)
SPRY icon

Connor, Clark & Lunn Investment Management (CC&L)’s ARS Pharmaceuticals SPRY Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-80,641
Closed -$851K – 1588
2024
Q4 		$851K Buy
80,641
+3,433
+4% +$48.1K ﹤0.01% 991
2024
Q3 		$1.12M Buy
+77,208
New +$918K 0.01% 846

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SPRY Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of ARS Pharmaceuticals (SPRY) in Q1 2025, closing a stake of 80,641 shares — an estimated $851K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SPRY in Q3 2024 and held it in 2 quarters. The position peaked at $1.12M in Q3 2024. 184 funds tracked by Wall St. Rank hold SPRY as of Q1 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining ARS Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 80,641 ARS Pharmaceuticals shares in Q1 2025, an estimated $851K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s ARS Pharmaceuticals position peaked at $1.12M in Q3 2024.
  • 184 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.